Exenatide News and Research

RSS

Exenatide (marketed as Byetta) is one of a new class of medications (incretin mimetics) approved for the treatment of diabetes mellitus type 2.

Oramed Pharmaceuticals receives Japanese patent for innovative oral delivery technology

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has received approval for a key patent by the Japanese Patent Office.

3 Apr 2013

New study associates commonly used diabetes drugs with pancreatic cancer risk

ndividuals who had taken a type of drug commonly used to treat Type 2 diabetes showed abnormalities in the pancreas, including cell proliferation, that may be associated with an increased risk of neuroendocrine tumors, according to a new study by researchers from UCLA and the University of Florida.

28 Mar 2013

GLP-1 pancreatitis concerns justified

Study results have raised further concerns over a link between pancreatitis and the use of glucagon-like peptide-1 (GLP-1)-based therapies for patients with Type 2 diabetes.

28 Feb 2013

GLP-1 may increase risk of hospitalization for people with acute pancreatitis

People who take the newest class of diabetes drugs to control blood sugar are twice as likely as those on other forms of sugar-control medication to be hospitalized with pancreatitis, Johns Hopkins researchers report.

25 Feb 2013

Oramed to submit new oral insulin IND with FDA

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has been in communication with the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application for oral insulin.

15 Feb 2013

GLP-1 receptor agonists associated with reduced BMI in adolescents with severe obesity

Preliminary evidence from a clinical trial suggests that treatment with glucagon-like peptide-1 (GLP-1) receptor agonists was associated with reduced body mass index and body weight in adolescents with severe obesity, according to a report published Online First by JAMA Pediatrics, a JAMA Network publication.

5 Feb 2013

Oramed files IND with FDA to begin ORMD-0801 Phase 2 trial for type 2 diabetes

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a Phase 2 clinical trial of its orally ingested insulin candidate, ORMD-0801.

9 Jan 2013

EU approves Forxiga for treatment of type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved Forxiga (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union. Forxiga is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body, a unique mode of action not seen in any other currently available treatments for type 2 diabetes.

15 Nov 2012

Results from liraglutide and exenatide head-to-head comparison trial on type 2 diabetes

A direct, head-to-head comparison of two of the newer treatments available for type 2 diabetes yielded mixed results.

7 Nov 2012

Diabetes drug could treat illicit drug addiction

Researchers have found that a drug currently used to treat Type 2 diabetes could treat addiction to drugs such as cocaine.

26 Oct 2012

Intarcia announces results from ITCA 650 phase 2 study on type 2 diabetes

Intarcia Therapeutics, Inc. announced that an analysis of the results of a phase 2 clinical study of ITCA 650 (continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes will be presented at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany on Wednesday, October 3, 2012.

29 Sep 2012

Extended release exenatide outperforms twice daily regimen

Once-weekly extended-release exenatide is a more effective treatment than twice-daily exenatide at improving glucose control among Japanese individuals with diabetes, report researchers.

24 Sep 2012

Bristol-Myers Squibb completes acquisition of Amylin

Bristol-Myers Squibb Company and AstraZeneca announced that following the successful completion of the acquisition of Amylin Pharmaceuticals by Bristol-Myers Squibb, AstraZeneca has made an initial payment of approximately $3.2 billion to Amylin Pharmaceuticals, now a wholly-owned subsidiary of Bristol-Myers Squibb.

10 Aug 2012

Scientists identify mechanisms by which GLP-1 protects against kidney disease, diabetes

Scientists at Joslin Diabetes Center have identified biological mechanisms by which glucagon-like peptide-1 (GLP-1), a gut hormone, protects against kidney disease, and also mechanisms that inhibit its actions in diabetes.

24 Jul 2012

Bristol-Myers Squibb to acquire Amylin

Bristol-Myers Squibb Company and Amylin Pharmaceuticals, Inc. announced today that Bristol-Myers Squibb will acquire Amylin for $31.00 per share in cash, pursuant to a cash tender offer and second step merger, or an aggregate purchase price of approximately $5.3 billion.

2 Jul 2012

Exenatide ‑ a better alternative for add-on therapy?

Twice-daily exenatide may offer advantages over the standard glimepiride in patients with Type 2 diabetes inadequately controlled by metformin, suggest findings published in The Lancet.

19 Jun 2012

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Amylin Pharmaceuticals, Inc. and Alkermes plc today announced results from the long-term extension of the DURATION-1 study, which showed that BYDUREON (exenatide extended-release for injectable suspension), the first and only once-weekly treatment for type 2 diabetes, was associated with clinically significant and sustained improvements in glycemic control during four years of treatment in adults with type 2 diabetes.

11 Jun 2012

Exendin-4 drug effectively suppresses craving for food

A drug made from the saliva of the Gila monster lizard is effective in reducing the craving for food. Researchers at the Sahlgrenska Academy, University of Gothenburg, have tested the drug on rats, who after treatment ceased their cravings for both food and chocolate.

16 May 2012

European Commission grants marketing authorization for use of BYETTA with basal insulin

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced today that the European Commission has granted marketing authorization to BYETTA (exenatide twice-daily) as an adjunctive therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents.

23 Mar 2012